A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.

ABSTRACT:

Aims

Relaxin-2, a well-known human hormone primarily associated with pregnancy, has shown promising cardiovascular benefits in both pre-clinical models and clinical trials. However, its therapeutic potential has been limited due to the short half-life and the short duration of treatment. To address this, we developed AZD3427, a novel long-acting relaxin-2 analogue, and assessed its efficacy during prolonged treatment in a large animal model with cardiac dysfunction.

Methods and results

Extensive protein engineering resulted in AZD3427, a novel fusion protein, which closely mimics the natural hormone's structure and consists of a single relaxin-2 and the Fc fragment of human IgG1 to extend its half-life. AZD3427 exhibits an improved pharmacokinetic profile, allowing for weekl

SUBMITTER: Papworth M 

PROVIDER: S-EPMC12160805 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature